Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double‐blinded, placebo‐controlled studies (CIMPASI‐1 and CIMPASI‐2)
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the American Academy of Dermatology"
DOI: 10.1016/j.jaad.2018.04.012
Abstract: Background Certolizumab pegol, the only Fc‐free, PEGylated anti–tumor necrosis factor biologic, demonstrated clinically meaningful improvements suggestive of a positive risk‐benefit balance in phase 2 studies in adults with moderate‐to‐severe chronic plaque psoriasis. Objective Assess certolizumab… read more here.
Keywords: plaque psoriasis; certolizumab; placebo; treatment ... See more keywords
The Unspoken Barriers to Treatment for Chronic Plaque Psoriasis.
Sign Up to like & getrecommendations! Published in 2023 at "Clinical and experimental dermatology"
DOI: 10.1093/ced/llad186
Abstract: Research on minority groups in Dermatology is limited. Dermatologists should be vigilant to ensure that we are well-informed and respectful of the social and cultural traditions of our patients. In doing so, we can foster… read more here.
Keywords: barriers treatment; chronic plaque; treatment chronic; dermatology ... See more keywords
Switching from one infliximab biosimilar (CT‐P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Dermatology"
DOI: 10.1111/bjd.19013
Abstract: CT-P13 and SB2 are two distinct biosimilars of the reference originator anti-tumour necrosis factor alpha monoclonal antibody infliximab. Real-life evidence has shown that the switch from infliximab originator to CT-P13 did not impair overall clinical… read more here.
Keywords: infliximab; chronic plaque; p13; sb2 ... See more keywords
Consensus on the place in therapy of TNF‐α inhibitors in the treatment of patients with chronic plaque psoriasis
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the European Academy of Dermatology and Venereology"
DOI: 10.1111/jdv.16380
Abstract: Biologics are a fundamental therapeutic resource for patients with moderate to severe chronic plaque psoriasis because they well conjugate effectiveness and safety. Several classes of biologics are available, including TNF-α inhibitors (infliximab, etanercept, adalimumab and… read more here.
Keywords: chronic plaque; place therapy; consensus place; tnf inhibitors ... See more keywords
Evaluation of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Chronic Plaque Psoriasis
Sign Up to like & getrecommendations! Published in 2022 at "Indian Journal of Dermatology"
DOI: 10.4103/ijd.ijd_935_21
Abstract: Background: Psoriasis is a common inflammatory dermatological condition and affects 2–3% population worldwide. Psoriasis area and severity index (PASI) and body surface area (BSA) are two commonly used scales used to measure disease severity in… read more here.
Keywords: lymphocyte ratio; chronic plaque; ratio; psoriasis patients ... See more keywords
Atorvastatin as adjunctive therapy for chronic plaque type psoriasis versus betamethasone valerate alone: A randomized, double-blind, placebo-controlled trial
Sign Up to like & getrecommendations! Published in 2017 at "Indian Journal of Dermatology, Venereology and Leprology"
DOI: 10.4103/ijdvl.ijdvl_425_16
Abstract: Background: Psoriasis is a T helper 1 cell-mediated chronic inflammation. Statins have been found to have anti-inflammatory and immunomodulatory effects targeting T helper 1 cells and thus, are being investigated as treatments for psoriasis. Aims:… read more here.
Keywords: psoriasis; atorvastatin; treatment; chronic plaque ... See more keywords
In chronic plaque psoriasis, roflumilast cream safely increased likelihood of clear or almost clear state at 6 weeks
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Internal Medicine"
DOI: 10.7326/acpj202011170-055
Abstract: SOURCE CITATION Lebwohl MG, Papp KA, Stein Gold L, et al. Trial of roflumilast cream for chronic plaque psoriasis. N Engl J Med. 2020;383:229-39. 32668113. read more here.
Keywords: chronic plaque; plaque psoriasis; roflumilast cream;